Reconstitution of immunodeficient SCID/beige mice with human cells: applications in preclinical studies.
Experimental studies of the in vivo behaviour of human cells and tissues have become possible with the development of immunodeficient mice strains. Such mice accept readily allogeneic or xenogeneic grafts, including grafts of human cells or tissues, without rejection. In this review we describe different immunodeficient mouse strains that have been used for reconstitution by human immune cells. We subsequently go through the experience that we and others have had with reconstitution, and mention the adverse effects, in particular xenogeneic graft versus host reactions. The use of haematopoietic stem cells avoids such reactions but the immunological reconstitution may take several months. We then report the use of immunodeficient mice for the study of chronic vascular rejection of human mesenteric arteries due to cellular or humoral alloreaction. We have shown that SCID/beige mice grafted with a human artery at the place of the aorta developed a thickening of the intima of the human artery after 5-6 weeks, when they were reconstituted with spleen cells from another human donor. The thickening is mainly due to a proliferation of smooth muscle cells. The same type of lesion developed if they received injection of antibodies towards HLA class I antigens. The arteries of the mouse did not develop any lesion. The arterial lesions closely resembled those seen after clinical organ transplantation. Mice that received spleen cells from the same human donor developed little or no lesions. An important aspect of this experimental transplantation model is the possibility to test drugs that may be used in clinical transplantation. In recent experiments we have shown that novel immunosuppressive drugs can inhibit the hyperproliferation of smooth muscle cells in vitro. Preclinical testing in reconstituted SCID/beige mice grafted with human arteries will permit the evaluation of the potential use of these drugs to prevent chronic vascular rejection. The model also allows pharmacodynamic studies that give information on the biological impact of different drugs that may be used in experimental or clinical transplantation.
Thomsen
Mogens
M
Institute of Molecular Medicine of Rangueil (I2MR), Centre Hospitalier Universitaire de Rangueil, BP 84225, 31432 Toulouse Cedex 4, France. thomsen@toulouse.inserm.fr
Galvani
Sylvain
S
Canivet
Cindy
C
Kamar
Nassim
N
Böhler
Torsten
T
D000818:Animals; D006084:Graft Rejection / Q000276:immunology* / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D017710:Lymphocyte Transfusion; D008638:Mesenteric Arteries / Q000637:transplantation*; D051379:Mice; D016513:Mice, SCID; D008954:Models, Biological; D013045:Species Specificity; D013154:Spleen / Q000276:immunology; D033581:Stem Cell Transplantation
D007166:Immunosuppressive Agents